2924-67-6

Usage

Uses

Used in Pharmaceutical Industry:
Fluoresone is used as a fluorophore for fluorescence microscopy and chemical analysis, aiding in the detection and visualization of biological molecules and processes. Its strong fluorescence and high quantum yield make it an ideal tool for these applications.
Used in Cosmetic Industry:
In the cosmetic industry, fluoresone is used as a component in the production of dyes and pigments. Its vibrant color and fluorescence properties contribute to the development of innovative cosmetic products.
Used in Semiconductor Industry:
Fluoresone is employed in the semiconductor industry for its optical and electronic properties, which are beneficial in the creation of advanced materials and devices.
Used in Organic Synthesis:
Fluoresone is used as a chemical probe and a key intermediate in the synthesis of various organic compounds, contributing to the advancement of organic chemistry.
Used in Biological Research:
As a chemical probe, fluoresone is utilized in biological research to study molecular interactions and mechanisms, taking advantage of its fluorescence properties for tracking and imaging purposes.
It is crucial to handle fluoresone with care due to its potential health risks if not used properly. Its applications across different industries highlight the versatility and importance of this fluorescent organic compound in modern scientific and technological advancements.

InChI:InChI=1/C8H9FO2S/c1-2-12(10,11)8-5-3-7(9)4-6-8/h3-6H,2H2,1H3

Upstream product

• 824-80-6 sodium 4-fluorobenzenesulfinate 
• 75-03-6 ethyl iodide 
• 462-06-6 fluorobenzene 
• 594-44-5 Ethanesulfonyl chloride 
• 14752-66-0 sodium p-chlorobenzenesulphinate 
• 371-40-4 4-fluoroaniline 
• 74-96-4 ethyl bromide 
• 349-88-2 4-Fluorobenzenesulfonyl chloride 
• 64-17-5 ethanol 
• 2266-41-3 4-fluorobenzenesulfonylhydrazide 
• 108-90-7 chlorobenzene 
• 371-42-6 4-Fluorothiophenol 
• 7205-80-3 1-(ethylsulfonyl)-4-chlorobenzene 
• 2924-75-6 1-(Ethylthio)-4-fluorobenzene 

Downstream Products

• 1227385-01-4 [4-(4-ethanesulfonyl-phenoxy)-6-fluoro-3-methyl-naphthalen-2-yl]-acetic acid methyl ester 
• 1132754-31-4 4-(ethylsulfonyl)-1-fluoro-2-nitrobenzene 
• 1352570-04-7 (S)-2-(3-(4-(ethylsulfonyl)phenoxy)-5-(1-hydroxypropan-2-yloxy)phenyl)pyrimidin-4(3H)-one 
• 1352571-49-3 C₃₆H₄₆N₂O₇SSi 
• 1227384-93-1 [4-(4-ethanesulfonyl-phenoxy)-6-fluoro-naphthalen-2-yl]acetic acid methyl ester 
• 929212-85-1 bis(4-ethanesulfonyl-benzene)disulfide 

Relevant academic research and scientific papers

Iodine-Mediated Sulfenylation of Imidazo[1,2- a ]pyridines with Ethyl Arylsulfinates

A simple iodine-mediated approach is reported for the synthesis of sulfenylated imidazo[1,2- a ]pyridines through the reaction of imidazo[1,2- a ]pyridines with ethyl arylsulfinates under mild conditions. The reaction scope was investigated, and a plausible mechanism is proposed to elucidate the reaction process and activation mode. The results indicate that ethyl sulfinates are efficient sulfur sources for the construction of C-S bonds.

PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF

Compounds having activity as chemotherapeutic agents are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein R1a, R1b, R1c, R1d, L, and are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods for treating cancer (e.g., hematological cancers) are also provided.

Bromine structural domain inhibitor compound and application thereof

The invention relates to a bromine structural domain inhibitor and provides a compound shown in a general formula I, pharmaceutical salt, an enantiomer, a diastereoisomer, an atropisomer, racemate, apolymorphic substance and solvate of the compound or an isotope labelled compound (including a deuterium substituted compound), a preparation method of the compound, pharmaceutical composition containing the compound and an application of the above components in pharmaceuticals.

BROMODOMAIN INHIBITORS

Provided are compounds of formula (I),wherein R 1, Y, X 1, X 2, R 2, R 3, R 4, R 5, R 6 and m have any of the values defined in the specification and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).

COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREAST CANCER

The present invention provides novel methods of treating triple-negative breast cancer (TNBC). In certain embodiments, the methods of the invention do not require the use of ionizing radiation therapies. In other embodiments, the methods of the invention do not harm non-cancerous cells.

Imidazo pyrazine compound, medicine composition of imidazo pyrazine compound and purpose of imidazo pyrazine compound

The invention provides an imidazo pyrazine derivative, a preparation method of the imidazo pyrazine derivative and a purpose of the imidazo pyrazine derivative as medicine. The invention provides a compound shown by a formula (I) and a physiologically acceptable salt, wherein each sign is defined as the specification. The compound can be combined with protein having the bromodomain structure domain so as to regulate the downstream signal path and to achieve a specific function; the compound can be used for various diseases relevant to the bromodomain structure domain protein; the compound can interfere with the combination of the acetylated histone and the Brd4 with the bromodomain structure domain; further, the transcription of the cancer gene and other relevant target genes is reduced, so that the compound can become effective treatment medicine for tumor.

DIHYDRO-PYRROLOPYRIDINONE INHIBITORS

The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, and R5 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

BROMODOMAIN INHIBITORS

The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

BROMODOMAIN INHIBITORS

The present invention provides for compounds of formula (I). wherein Rx, Ry, Rx1, L1, G1, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Highly atom-economic, catalyst- and solvent-free oxidation of sulfides into sulfones using 30% aqueous H2O2

Highly atom-efficient oxidation of sulfides into sulfones under solvent- and catalyst-free reaction conditions using a 30% aqueous solution of H 2O2 at 75 °C is reported. A structurally diverse set of phenyl alkyl-, phenyl benzyl-, benzyl alkyl-, dialkyl-, heteroaryl alkyl- and cyclic sulfides were transformed into sulfones regardless of the aggregate state and electronic nature of the substituents. In spite of the heterogeneous reaction mixtures throughout the work, no difficulties with stirring and reaction progress were noted. In numerous cases, only 10 mol% excess of H 2O2 was used, thus contributing considerably to the high atom economy of the process. Some solid substrates required a variable excess of hydrogen peroxide; however, the reactions were performed strictly without organic solvents. The transformation was demonstrated to be amenable for scale-up with both liquid and solid sulfides. In addition, isolation and purification of the crude products can be simply done with only filtration and crystallization.